Caris Life Sciences (CAI) Accumulated Expenses (2024 - 2026)

Caris Life Sciences' Accumulated Expenses history runs 3 years deep, the most recent figure standing at $73.9 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses changed N/A year-over-year to $73.9 million in Q1 2026; TTM through Mar 2026 was $73.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $87.8 million, up 13.19% from the prior year.
• Accumulated Expenses retreated to $73.9 million in Q1 2026 per CAI's latest filing, from $87.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $87.8 million in Q4 2025 and bottomed at $56.9 million in Q3 2025.
• The 3-year median for Accumulated Expenses is $73.9 million (2026), against an average of $71.5 million.
• Biggest YoY gain for Accumulated Expenses was 13.19% in 2025; the steepest drop was 13.19% in 2025.
• Year by year, Accumulated Expenses stood at $77.5 million in 2024, then climbed by 13.19% to $87.8 million in 2025, then dropped by 15.78% to $73.9 million in 2026.
• Per Business Quant, the three latest CAI Accumulated Expenses figures stand at $73.9 million (Q1 2026), $87.8 million (Q4 2025), and $56.9 million (Q3 2025).